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Abstract. Nanoparticles, such as liposomes, polymeric micelles, lipoplexes and polyplexes are frequently
studied as targeted drug carrier systems. The ability of these particles to circulate in the bloodstream for
a prolonged period of time is often a prerequisite for successful targeted delivery. To achieve this,
hydrophilic Fstealth_ polymers, such as poly(ethylene glycol) (PEG), are used as coating materials. Such
polymers shield the particle surface and thereby reduce opsonization by blood proteins and uptake by
macrophages of the mononuclear phagocyte system. Yet, after localizing in the pathological site,
nanoparticles should deliver their contents in an efficient manner to achieve a sufficient therapeutic
response. The polymer coating, however, may hinder drug release and target cell interaction and can
therefore be an obstacle in the realization of the therapeutic response. Attempts have been made to
enhance the therapeutic efficacy of sterically stabilized nanoparticles by means of shedding, i.e. a loss of
the coating after arrival at the target site. Such an Funmasking_ process may facilitate drug release and/or
target cell interaction processes. This review presents an overview of the literature regarding different
shedding strategies that have been investigated for the preparation of sterically stabilized nano-
particulates. Detach mechanisms and stimuli that have been used are described.
KEY WORDS: long-circulating nanoparticles; nanomedicines; poly(ethylene glycol); shedding; Fstealth_
coatings.
INTRODUCTION
Nanoparticles, such as liposomes, polymeric micelles,
lipoplexes and polyplexes have been extensively studied as
targeted drug carrier systems over the past three decades. A
wide variety of active agents can be incorporated into or
complexed with these particles varying from low molecular
weight drug molecules to macromolecules such as proteins
and nucleic acids (1). An important requirement to the
systemic intravenous use of this targeted nanomedicine
approach is the ability of the nanoparticles to circulate in
the bloodstream for a prolonged period of time. To achieve
this, often poly(ethylene glycol) (PEG) is used as a coating
material. It is generally assumed that PEG creates a so-called
Fsteric stabilization_ effect: the PEG molecules form a
protective hydrophilic layer on the surface of the nano-
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ABBREVIATIONS: BVEP, (R)-1,2-di-O-(1¶Z,9¶Z-octadecadienyl)-
glyceryl-3-(w-methoxy-poly(ethylene glycolate); CHEMS, Cholesteryl
hemisuccinate; CerC24,C 20,C 14,C 8, Ceramides with acyl chains lengths
of 24, 20, 14, and 8 carbon atoms; c-TEM, Cryo transmission electron
microscopy; DAG, Diacylglycerol = 1,2-diacylglycerol; DHCh,
Hydrogenated cholesterol; DMA, 1,2 dimyristyloxypropyl-3-amine;
DMG, 1,2-dimyristoylglycerol; DMPE, Dimyristoyl phosphatidylethanol-
amine = 1,2 dimyristoyl-sn-glycero-3-phosphoethanolamine; DOG, 1,2-
dioleyl-rac-glycerol; DODAC, N,N-dioleyl-N,N-dimethylammonium
chloride; DODAP, 1,2-dioleoyl-3-dimethylammonium-propane; DOPE,
Dioleyl phosphatidylethanolamine = 1,2-dioleoyl-sn-glycero-3-phosphati-
dylethanolamine; DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane;
DPG, 1,2-dipalmitoylglycerol; DPPE, Dipalmitoyl phosphatidylethanol-
amine = 1,2 dipalmitoyl-sn-glycero-3-phosphoethanolamine; DSA, 1,2
distearyloxypropyl-3-amine; DSG, 1,2-distearoylglycerol; DSPA, 1,2-
distearoyl-sn-glycerol-3-phosphatidic acid; DSPE, Distearoyl phospha-
tidylethanolamine = 1,2 distearoyl-sn-glycero-3-phosphoethanolamine;
DTB, Dithiobenzyl carbamate; DTH, Dithio-3-hexanol; DTP, 3,3¶-
dithiopropionate; DTT, Dithiothreitol; DXR, Doxorubicin; EGF,
Epidermal growth factor; FRET, Fluorescence energy transfer;
GFLG, Gly-Phe-Leu-Gly; Hz, Hydrazone; LDP, Lipid-DNA particles;
MEND, Multifunctional envelope-type nanodevice; MMP, Matrix
metallo proteinases; NLP, Nanoparticles with encapsulated plasmid
DNA; ODN, Oligodeoxynucleotides; PC, Phosphatidylcholine = 1,2
diacyl-sn-glycero-3-phosphocholine; PE, Phosphatidylethanolamine = 1,2
diacyl-sn-glycero-3-phosphoethanolamine; PEG, Poly(ethylene glycol);
PEI, Poly ethylene imine; PEOS, Poly(ethylene oxide sulfide); PFV,
Programmable fusogenic vesicle; PHEG, Poly(hydroxyalkyl L-glutamine);
PHEA, (Poly(hydroxyalkyl L-asparagine); PIC, Polyion complex; PLL,
Poly-L-lysine; POD, PEG2000-diortho ester-distearoyl glycerol;
polyDMAEMA, Poly(2-(dimethylamino)ethyl methacrylate);
polyHPMA, Poly(N-(2-hydroxypropyl)methacrylamide); PPD, PEG-
peptide–DOPE conjugate; PS, Phosphatidylserine; PSD,
Poly(methacryloyl sulfadimethoxine); SAINT12:0, 14:0, 16:0, 18:0, N-
methyl-4-alkylpyridinium chloride with alkyl chains lengths of 12, 14,
16, or 18 carbon atoms; SALP, Stabilized antisense-lipid particles;
siRNA, Small interfering RNA; SPLP, Stabilized plasmid-lipid particles.particle that opposes interaction with blood components. As
a result, the PEG coating reduces uptake by macrophages of
the mononuclear phagocyte system (MPS) and provides
relatively long plasma residence times (2). Until now, PEG
is still the most widely used material for achieving steric
stabilization. Nevertheless, successful attempts have been
made to design alternative polymers, for example polymers
based on poly(oxazoline) (3), polyvinyl alcohol (4), poly
(glycerol) (5), poly-N-vinylpyrrolidone (6), poly[N-(2-
hydroxypropyl)methacrylamide] (7) and poly(amino acid)s
(8) were investigated (for reviews, see (1,9,10)). For all these
coating materials, prolonged circulation times of nanopar-
ticles as compared to non-coated nanoparticles have been
reported. It has to be realized, however, that steric stabiliza-
tion is not desirable for all steps in the drug targeting process.
The prolonged circulation time is needed to enable extrav-
asation at sites with increased vascular permeability such as
tumors and inflamed sites (enhanced permeability and
retention (EPR) effect) (11). But after localizing in the
pathological site, nanoparticles should deliver their contents
in an efficient manner to achieve a sufficient therapeutic
response. The polymer coating, however, may hinder drug
release and target cell interaction and can therefore be an
obstacle in the realization of the therapeutic response (12–
14). Attempts have been made to enhance the therapeutic
efficacy of sterically stabilized nanoparticles by means of
shedding, i.e. a loss of the coating after arrival at the target
site. This Funmasking_ process may facilitate drug release
and/or target cell interaction processes. The shedding con-
cept provides a potential solution for several situations in
which the polymer coating can have a negative effect on the
delivery process (summarized in Fig. 1). Shedding can
promote:
Extracellular/Intracellular Release
If, within the pathological site, extracellular release of
the drug from the extravasated nanoparticle is sufficient, e.g.
in the case of small molecules that easily pass target cell
membranes, a delay in destabilization of the carrier due to its
steric protection may limit the therapeutic availability of the
drug within the target region. The shedding of the coating
after arrival at the target site can lead to accelerated drug
release. For example, if a non-bilayer forming lipid is
retained in liposomes using a PEG-conjugate, the removal
of the polymer coating would result in membrane destabiliz-
ing phase changes and consequently drug leakage (Fig. 1a).
Obviously, besides for extracellular release, also for intracel-
lular release shedding can be beneficial.
Cellular Interaction
In cases where the drug is not able to cross cell membranes
(e.g. proteins, genes), extracellular release is not an option and
it is required that the nanoparticles are internalized by the
target cell to deliver the drug at the appropriate intracellular
location. The polymer coating, however, interferes with the
ability of the nanoparticles to interact with the target cells.
Cellular interaction can be enhanced if a positive charge is
present on the surface of the particles. Positively charged
particles have been shown to bind to negatively charged plasma
membranes with subsequent internalization via endocytosis
(15). The polymer coating shields the charged surface during
circulation and therefore prevents rapid clearance and aggre-
gation due to electrostatic interactions with blood components.
Shedding of the coating after entry of the target site would
restore the possibility of interactions with the target cell
membranes and thereby increase cellular uptake (Fig. 1c). As
an alternative to introducing a positive charge, targeting
ligands (e.g. antibodies, antibody fragments, and peptides)
can be attached to the nanoparticle surface to induce
internalization via specific receptors. Often, targeting ligands
are being coupled to the terminal end of the PEG-chains.
However, coupling the ligand to the distal end of the polymer
chains can lead to an accelerated removal of the targeted
particles from the circulation, especially at higher ligand
densities (16). Moreover, the presence of targeting ligands
may evoke immune responses prohibiting repeated dosing of
the formulation (17). The shedding principle is a solution to
avoid these problems. Ligands can be attached directly to the
outer particle surface and are therefore shielded by the
polymer coating during the circulation. Though the coating
inhibits the interaction between the targeting ligand and its
target receptor (18,19), shedding of the polymer coating from
the carrier would expose the ligand and make it available for
receptor interaction (Fig. 1b).
Cytosolic Delivery
Once the particles are internalized by the target cells via
endocytosis, they are often required to deliver their drug
contents to the cytosol. Due to the presence of degradative
enzymes and the relatively low pH present in the lysosomal
compartment, however, the active substance may be prone to
degradation before it reaches the cytosol. Moreover, the drug
may be too hydrophilic and/or too large to efficiently pass the
endo/lysosomal membranes. Both the degradation as well as
restricted membrane transport can be a problem, particularly
when delivering proteins or DNA. In these cases the cargo
must be protected and able to escape from the endo/
lysosomal compartment. Endosomal escape can be mediated
by fusogenic liposomes employing the lipid DOPE (20).
These liposomes by themselves do not show the needed
prolonged circulation times. If PEG is used as a sterically
stabilizing component, the fusogenic potential and conse-
quently the cytosolic delivery efficiency are unfortunately
substantially reduced (13). Shedding of the coating would
restore fusogenicity of the liposomes and allow for endo-
somal escape (Fig. 1d). Alternatively, to avoid inactivation of
the drug in the endosomal compartment, it has been reported
that cell-penetrating peptides, when attached to the surface
of the carrier, mediate cellular uptake in an endocytosis-
independent manner. Such peptides are shielded by the
coating during the circulation and subsequent shedding of
the coating at the target site exposes these peptides so
internalization of the carrier can occur.
Anti-PEG Immune Response After Administration
of PEGylated Carriers Containing Nucleic Acids
It has been reported that administration of nucleic acids
such as antisense oligodeoxynucleotides (ODN), plasmid
56 Romberg, Hennink and StormDNA or small interfering RNA (siRNA) formulated in PEG-
liposomes can raise an antibody-response against PEG, which
may result in morbidity and rapid plasma elimination of
liposomes administered with subsequent injections (21,22).
PEG is generally considered to be non-immunogenic (23).
However, when PEG-lipids are used as coatings for nucleic
acid-carrying liposomes, the nucleic acids can act as a potent
adjuvant, resulting in an immune response against PEG. If
the PEG-coating is gradually removed after administration,
the immunogenicity of these nucleic acid containing particles
is expected to be lower.
This review presents an overview of the literature
regarding different shedding strategies that have been
investigated for the preparation of sterically stabilized nano-
Fig. 1. Schematic representation of the different shedding applications following the localization of sterically stabilized nanoparticles at the
target site. Top panel: extracellular shedding leading to: a extracellular release of the entrapped drug and subsequent uptake of the drug, b
exposure of a targeting ligand and subsequent receptor-mediated internalization and intracellular drug release and c exposure of a positively
charged surface and subsequent internalization and intracellular drug release. Bottom panel: d intracellular shedding after endocytosis and
subsequent drug release events.
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used are described.
SHEDDING APPROACHES
Shedding by Cleavage of a Linkage Between the Stabilizing
Polymer and Its Anchor
The coating polymer can be attached to a lipid anchor,
which allows grafting to a lipidic surface, e.g. liposomal
bilayers. A linker with a predetermined cleavage point
between the polymer chains and the anchoring moiety can
be introduced in this polymer–lipid conjugate. Chemical
stimuli, such as the presence of low pH or reducing agents,
and enzymatic stimuli, such as proteases, can induce cleavage
of the linker. For an overview of shedding approaches using
cleavable linkers see Table I.
Low pH-Induced Shedding
After entry into the target cell via receptor-mediated
endocytosis, which is the uptake process for most particulate
carriers, a lower pH is encountered in the endo/lysosomal
compartment (24). Endosomes display a pH around 5.5-6.0
and lysosomes around 4.5. The extracellular pH within
pathological sites such as tumors, inflammatory tissue and
myocardial ischemia can also be lower than the physiological
pH (25–27). If pH-sensitive functional groups are applied as
linkers between the polymer coating and its anchor, they may
undergo protonation in the low pH environment, leading to
hydrolysis of the sensitive bond and therefore to detachment
of the polymer molecule. For nanoparticulate systems the
diorthoester, the orthoester, the vinyl ether, the phosphor-
amidate, the hydrazone, and the b-thiopropionate linker have
been applied as acid-sensitive linkers. An overview of the
hydrolysis reactions involved is given in Fig. 2. Besides
covalent bonds, linking of the coating to the carrier by
electrostatic attraction, which are reduced or even abrogated
at lower pH, has been pursued.
The diorthoester linker. The diorthoester bond (Fig. 2a)
is one of the most pH-sensitive functional groups. Orthoest-
ers are relatively stable under neutral conditions, but upon
protonation they hydrolyze quickly due to the formation of a
stabilized dialkoxy carbonium intermediate (28). The group
of Szoka focused on the design of a sheddable coating which
stabilizes the fusogenic DOPE in liposomes at neutral pH.
PEG was linked to distearoyl glycerol via a diorthoester bond
(PEG2000-diortho ester–distearoyl glycerol (POD) conju-
gate). Hydrolysis of this bond at the low endosomal pH was
expected to result in destabilization of the DOPE-liposomes
by promoting L  HII phase transition and thereby to
mediate fusion with the endosomal membrane and contents
release into the cytosol (29). While most of the POD
conjugate remained intact over 3 h of incubation at 37-C
and pH 7.4, complete degradation occurred within 1 h at pH
4 and 5. A fluorescence quenching assay was used to study
the leakage and thereby destabilization of POD-liposomes.
Liposomes with 10 mol% of POD were stable in alkaline
buffer for 2 weeks (pH 8.5). At pH 5-6, resembling endo-
somal conditions, the liposomes collapsed within 10–100 min,
showing extensive aggregation and contents leakage. Increas-
ing amounts of POD on the liposome surface resulted in
slower leakage kinetics (30). Kinetic studies in mice were
performedwiththePOD/DOPEliposomesandrevealedahalf-
lifeof194min(29). In comparison, PEG/DOPE liposomes had
a half-life of 295 min. Based on the results of the leakage and
lipid mixing assays, a Fminimum surface shielding model_ was
proposed (31). Two phases of release were observed: an initial
lag phase with only little leakage and a burst phase with
extensive leakage. Upon pH decrease, hydrolysis of the
diorthoester bond results in a reduction of the amount of
POD molecules on the liposome surface (lag phase). Below a
certain threshold level of surface-attached POD, intervesicular
Table I. Shedding Approach: Cleavage of a Linker Between the Stabilizing Polymer and its Anchor
Stimulus Linker
Aimed
Shedding Site
Type
nano-particle References
In vivo
Studies (Ref)
Low pH Diorthoester Extracellularly
a,
endosome
Liposome,
NLP, SPLP
(29–32)+ ( 29)
b
Orthoester Extracellularly
a Lipoplex (33) j
Vinylether Extracellularly
a
endosome
Liposome (34–36,38) j
Phosphoramidate Endosome ODN micelle (39) j
Hydrazone Extracellularly
a,
endosome
Micelles, liposomes,
polyplexes
(40,41)+ ( 41)
c
b-thiopropionate Endosome ODN micelle
siRNA micelle
(42–44) j
Electrostatic Endosome Polyplex (45,46) j
Reducing
agents
Disulfide Extracellularly,
intracellularly
in endo/ lysosome
and cytosol
Liposome, polyplex (49–54)+ ( 50,51)
b,d
Proteases Peptide Endo/lysosome,
extracellularly
a
Liposome, MEND (51,59)+ ( 51,59)
b,c
aIn tumor, inflamed or ischemic tissue
bStudies on pharmacokinetics and/or biodistribution
cStudies on gene expression
dStudies on therapeutic effects
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(burst phase). The advantage of the use of the POD conjugate
is that rapid hydrolysis occurs at a mildly acidic pH. This
property makes the POD conjugate especially attractive for
drug delivery situations in sites where the pH reduction is only
one pH unit or less, such as in inflamed or malignant tissue.
Besides application for liposomes, the use of POD as a
sterically-stabilizing coating has been studied for nonviral
gene delivery vectors, in this particular case lipoplexes (32).
Cellular uptake of these particles is mediated by electrostatic
interaction of the positively charged lipoplexes with the
negatively charged cell membranes. A cleavable PEG-
conjugate attached to the surface of these carriers should
shield the positive charge in the circulation and thereby
reduce unspecific interactions with blood components and
increase the circulation half-life. On the other hand, the
cleavable PEG coating should still allow successful delivery
of the DNA and subsequent protein expression. To achieve
this, stabilized plasmid-lipid particles (SPLP), composed of
the cationic lipid 1,2-dioleyl-3-trimethylammonium-propane
(DOTAP), DOPE, POD and plasmid DNA were designed.
Shedding of the PEG-coating was assessed by studying the
pH-and time-dependent collapse of the particles using
dynamic light scattering. While pH-insensitive PEG-SPLP
did not collapse at low pH, POD-SPLP with 13 mol% POD
collapsed within 110 min at pH 5.3, as evidenced by an
increase of the mean diameter of several hundreds of
nanometers. PEG-SPLP and POD-SPLP were taken up by
cultured CV-1 cells to a similar extent and in a similar
punctuate pattern, but only the latter showed considerable
gene transfection. This was likely a result of a faster endo-
somal escape mediated by shedding of the coating. POD
nanoparticles with encapsulated plasmid DNA (referred to as
NLP) showed superior transfection properties in CV-1 cells
as compared to a pH-insensitive control formulation (50–100
times higher transfection levels) (30). This was attributed to
an enhanced endosomal escape of the DNA of these
formulations, mediated by shedding of the coating. The
authors claimed the POD formulation (POD with PEG2000)
as the most optimal formulation when compared to formu-
lations with diorthoester conjugates with a PEG molecular
weight of 750 and 5,000, regarding small size, stability,
cytotoxicity, and transfection efficiency.
The orthoester linker. Besides the diorthoester bond,
also the orthoester bond (Fig. 2b) has been studied for its
applicability to mediate shedding. Four PEG–orthoester lipid
conjugates composed of either an octadecyl alkyl chain or a
cholesteryl group (hydrophobic anchor) and a PEG5000 chain
linked by either a six-membered or a five-membered
orthoester ring structure were synthesized by Masson et al.
(33). To assess the shedding potential, hydrolysis rates of
these conjugates were determined. At room temperature and
pH 7.5, conjugates were stable for several days. Hydrolysis at
pH 5 was the fastest for the conjugate with the cholesteryl
group and the six-membered ring orthoester and complete
within 1 h. Conjugates were used for the steric stabilization of
lipoplexes based on a cationic lipopolyamine, DOPE, and
plasmid DNA. Particle destabilization rates at lower pH were
highest when the six-membered ring orthoester conjugate
with the cholesteryl group was used. At pH 5 lipoplexes
prepared with this conjugate aggregated within 30 min.
Transfection studies in vitro revealed a 25-fold increase in
transfection of HeLa cells in case of lipoplexes prepared with
the most optimal PEG-orthoester lipid conjugate as com-
pared to lipoplexes coated with non-cleavable PEG.
The vinyl ether linker. The vinyl ether linkage (Fig. 2c)
was exploited by the group of Thompson to synthesize
different vinyl ether-linked PEG–lipid conjugates and devel-
op a shedding strategy for DOPE-based liposomes (34).
Upon protonation of the vinyl ether b-carbon of this
functional group, the double bond is cleaved releasing an
alcohol and an aldehyde. PEG of two chain lengths (PEG2000
Table III. Shredding Approach: Degradation of the Coating Material Itself
Coating Material Stimulus Aimed Shedding Site Nano-particle Type References In vivo Studies (Ref)
PEOS Reducing
agents
Cytosol Poly acrylic
acid-nanoparticle
(79) j
Poly(amino acid)s Proteases Endo/lysosome,
extracellularly
a
Liposome (80)+ ( 80)
b
aIn tumor, inflamed or ischemic tissue
bStudies on pharmacokinetics and/or biodistribution
Table II. Shredding Approach: Spontaneous Extraction out of the Nanoparticles
Exchangeable Anchor Nano-particle type References In vivo Studies (Ref)
Phosphatidylethanolamine Liposome, LDP (13,61–65)+ ( 61–63,65)
a,c,d
Ceramide Liposome, SPLP,
PFV, lipoplex
(66–75)+ ( 66,67,69,71,72)
a,b
Diacylglycerol Liposome, SPLP (21,22,76)+ ( 21,22,76)
a,b
Dialkyloxypropylamine SPLP (77)+ ( 77)
a,b
SAINT Lipoplex (78) j
aStudies on pharmacokinetics and/or biodistribution
bStudies on gene expression
cStudies on therapeutic effects
dStudy on shedding in the circulation
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or DOPE as the lipid anchor, respectively. To evaluate
shedding, the potential of these conjugates to promote low
pH-induced calcein release was investigated. Calcein was
released from the liposomes within the time scale of hours in
an acidic environment (pH<5). For example, the formulation
with 5 mol% of the PEG2000-vinyl ether–DOPE conjugate
showed only 14% calcein release at pH 7.4, whereas 95% of
the calcein was released at pH 3.5. This nearly complete
release, however, required 48 h of incubation. The rate of
shedding increased in the case of the DOPE-anchor systems
as the surface was negatively charged and therefore a higher
proton concentration is present at the carrier surface.
Furthermore, the vinyl ether bond orientation with respect
to the membrane bilayer likely played a critical role, as
shedding occurs more slowly if the sensitive linker is oriented
closer to the hydrophobic acyl chain region.
The vinyl ether bond was also used to link PEG5000 to a
hydrogenated cholesterol moiety (DHCh-MPEG5000)( 35).
Hydrolysis of the conjugate was slow with the reaction still
incomplete after 5 days at pH 4.5. Studies on the interaction
of fusogenic DOPE/DHCh-MPEG5000 liposomes with endo-
some-like membranes suggested that even upon prolonged
exposure to a low pH, fusion with endosome-like membranes
did not occur. The authors conclude from their findings that
the slow cleavage rate of the conjugate is insufficient to make
it applicable for shedding in vivo.
Improved properties of vinyl ether-linked PEG deriva-
tives were demonstrated in a subsequent publication (36). A
PEG5000-derivatized analogue of diplasmenylcholine with a
vinyl ether linkage ((R)-1,2-di-O-(1¶Z,9¶Z-octadecadienyl)-
glyceryl-3-(w-methoxy-poly(ethylene glycolate)), BVEP)
was synthesized and utilized to stabilize DOPE liposomes
(37). The shedding ability was assessed by analysis of the
hydrolysis kinetics of BVEP, dye release from BVEP/DOPE
liposomes and liposome fusion at low pH values. Eighty
percent of the BVEP was hydrolyzed at pH 4 after 60 min.
Liposomes containing 1-5 mol% of the BVEP showed only
little calcein release at neutral pH in buffer for up to one day.
Also in 10% serum, these formulations were relatively stable
(approx. 20% calcein leakage over 20 h) (38). The most
optimal liposome formulation regarding dye retention at
neutral pH and dye release at acidic pH (BVEP/DOPE 3:97)
showed a collapse at pH 4.5 within 3 h as shown by c-TEM.
However, at this pH calcein release kinetics (78% after 24 h)
and levels of membrane fusion (5% after 72 h) were low (36).
Several explanations for the slow kinetics were proposed: a
generally slow hydrolysis rate, alterations of the microenvi-
ronment at the hydrolysis site (e.g. a less acidic pH than in
the surrounding solution), and an inhibition of the DOPE
phase transition caused by e.g. retention of hydrolyzed PEG
on the liposome surface. The authors conclude that contents
release and membrane fusion were not rapid enough and
must be increased for application in vivo.
The phosphoramidate linker. The acid-induced shedding
approach was also applied to DNA/PEG hybrid micelles for
delivering ODN, which are able to bind to cytoplasmic
mRNA to block specific gene expression (39). Shedding of
the stabilizing PEG layer can be advantageous as PEG might
sterically hinder interaction of ODN with the target RNA
after ODN-PEG have been released into the cytosol. Jeong
et al. used an acid-cleavable phosphoramidate group (Fig. 2d)
to covalently link the ODN to PEG resulting in a diblock
copolymer-like structure. At a pH of 4.7, almost quantitative
linkage hydrolysis was achieved within 5 h. The negatively
charged ODN–PEG conjugate was complexed with the
cationic fusogenic peptide KALA to increase endosomal
escape. This resulted in polyelectrolyte complex micelles with
the PEG molecules forming the hydrophilic corona. A
comparison with a formulation bearing PEG with a non-
cleavable linker was not performed. Thus, although the
results on the delivery and antisense effect found in this
study were encouraging, they provide no evidence for a
benefit of the PEG shedding.
The hydrazone linker. Another linker that is sensitive to
low pH and therefore of potential value for use in sterically
stabilized nanoparticle systems is the hydrazone bond
(Fig. 2e). Sawant et al. designed micelles and liposomes with a
sheddable coating using the pH-sensitive hydrazone linker to
couple PEG to phosphatidylethanolamine (PEG-Hz-PE)
(40). The stability of PEG-Hz-PE micelles was assessed by
size exclusion chromatography. The micelles were intact after
20 min of incubation at room temperature at pH 10, whereas
at pH 7 the amount of micelles was reduced to 56% and at
pH 5 only 3% of the micelles were recovered. PEG-Hz-PE
micelles composed of PEG-PE (40 mol%) and PEG-Hz-PE
(54 mol%) were prepared. Biotin was included as a model
targeting ligand to be exposed after shedding. Biotin binding
R1
O R2 + R2 O
R1-OH
Vinylether hydrolysis
Phosphoramidate hydrolysis
P
H
N O
O
O
-
R2 R1 R2-OH + R1N-H2 H2PO4
- +
Diorthoester hydrolysis
O O
O
R1
O
O
O R2 H+/H2O
HO
O OH
O
O
O
+ R1-OH R2-OH
Orthoester hydrolysis
O
R2 O
O
R1
O
OH
R1 R2-OH +
O
+
N
N
H
R1
R
R2 O
N
H
R1
R
R2 H2N
+
Hydrazone hydrolysis
β-Thiopropionate hydrolysis
O S
O
R1 R2 R1-OH HO S
O
R2 +
H+/H2O
H+/H2O
H+/H2O
H+/H2O
H+/H2O
a
b
c
d
e
f
Fig. 2. Hydrolysis reactions relevant to acid-sensitive linkers used in
sheddable coatings. R1 contains the hydrophilic part of the molecule
(PEG), R2 contains the hydrophobic anchor, ODN or PLL, depend-
ing on the type of carrier.
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8 only 15% of the micelles were retained on the column, 75%
of the micelles were retained after 15 min incubation at pH 5,
due to exposure of the biotin ligand after shedding of the
PEG-coating. PEG-Hz-PE carriers were tested for associa-
tion and internalization by 3T3 cells (micelles) and U-87 MG
cells (liposomes) using fluorescence microscopy. For these
experiments, cell penetrating TAT moieties were used
instead of biotin groups. Micelles with 5 mol% of the TAT
peptide were only marginally associated with cells when kept
at pH 8, however association was clearly enhanced when
micelles were preincubated for 20–30 min at pH 5 before
adding them to cells. For liposomes with 9 mol% of the
cleavable PEG-Hz-PE, association with cells were at levels
comparable to the non-coated liposomes after preincubation
for 20 min at pH 5, indicating that the TAT function could
mediate association after shedding.
Walker and colleagues have reported on the synthesis of
several different poly-L-lysine (PLL)–PEG conjugates linked
via hydrazone bonds for non-viral gene delivery systems (41).
The two most promising candidates showed hydrolysis half-
lives of 30 min (acylhydrazone-linked PEG-conjugate) and
1.5 h (2-pyridylhydrazone-linked PEG-conjugate) at pH 7.4
and 37-C, but only 10% of the conjugates remained intact
after 10 min at pH 5 and 37-C. Shedding was assessed by
measuring changes in zeta potential and particle size of the
polyplexes. Polyplexes prepared without PEG-conjugates
aggregated after 1 h at 37-C in the presence of salt.
Polyplexes with the 2-pyridylhydrazone-linked and the acyl-
hydrazone-linked conjugates were stable for 5 h and 30 min
of incubation at pH 7.4 and 37-C, respectively. However, at
pH 5, within two hours (2-pyridylhydrazone-linked conju-
gate) and 30 min (acylhydrazone-linked conjugate), a maxi-
mum in surface charge and aggregation of polyplexes was
reached. Transfection studies with poly (ethylene imine)
(PEI)-based polyplexes shielded with hydrolysable PEG-
conjugates showed that transfection levels in different cell
types were similar to those obtained with non-shielded
polyplexes and were approximately 40–100 fold higher than
for a polyplex formulation with a non-hydrolysable PEG-
PLL conjugate. The authors assume that an improved endo-
somal escape of the DNA after shedding of the PEG-coating
is responsible for improved transfection activity. In a
subcutaneous mouse tumor model, epidermal growth factor
receptor (EGF) targeted polyplexes were used for transfec-
tion after intravenous administration. Polyplexes prepared
with the 2-pyridylhydrazone-linked conjugate showed more
than one order of magnitude higher luciferase expression in
the tumor when compared to polyplexes with a non-hydro-
lysable PEG-PLL conjugate. The authors suggest that
shedding increases the intracellular trafficking efficiency of
the polyplexes by increasing for example endosomal escape.
The b-thiopropionate linker. The group of Kataoka
investigated a b-thiopropionate linker (Fig. 2f) as acid-labile
ester group to link antisense ODN to PEG and form polyion
complex (PIC) micelles with these conjugates together with
linear PEI (42). At pH 7.4 almost no cleavage of the linker
was observed, however, 97% was cleaved after 24 h at pH
5.5. Size exclusion chromatography showed that at pH 5.5 the
PIC micelle peak completely disappeared after six hours.
Precipitation was observed in the samples. Micelles with the
b-thiopropionate linker had an increased antisense effect as
compared to micelles with an acid-insensitive linker (65% vs.
27% inhibition of luciferase gene expression) (43). The
authors conclude that the cleavage of the acid-labile linker
in the endosomes is an important requirement for the release
of the free ODN into the cytosol and subsequent antisense
effect. Besides ODN-mediated effects, successful gene si-
lencing was achieved with PIC micelles prepared by coupling
siRNA to PEG via the b-thiopropionate linker and complex-
ation with PLL (44).
Linking via electrostatic interactions. In addition to
covalent bonds, also non-covalent bonds have been exploited
for low-pH induced shedding. Finsinger and colleagues
designed PEG-peptide conjugates, containing negatively
charged glutamic acid residues, which bind electrostatically
to positively charged PEI-DNA complexes (45). These
conjugates reduced opsonization as compared to non-coated
polyplexes and were designed to dissociate from the PEI-
DNA complex at the low pH in endosomes due to
protonation of the negatively charged peptides. They were
equally effective in in vitro gene delivery when compared to
non-coated polyplexes. A similar approach was pursued by
Auguste et al. (46). Different PEG-polycation copolymers
were synthesized and adsorbed onto liposomes containing
the pH-sensitive lipid 1,2-dioleoyl-3-dimethylammonium-
propane (DODAP), which is neutral at pH 7.4 and positively
charged at pH 5.5. Lowering the pH from 7.4 to 5.5 was
expected to result in a positively charged liposome surface
and consequently desorption of the PEG-polycation copoly-
mers from the liposome surface. Indeed, copolymers with
PEG5000-pDMAEMA showed decreased association con-
stants upon lowering the pH from 7.4 to 5.5.
Sethuraman et al. designed poly(methacryloyl sulfadi-
methoxine)-block-PEG (PSD-b-PEG) copolymers, which
were adsorbed onto a positively charged DNA/PEI complex
at neutral pH due to the negatively charged PSD (47). Size
and zeta potential analysis of DNA/PEI/PEG-b-PSD poly-
plexes showed changes at a pH around 6.6, indicating
neutralization of PSD and detaching of the PEG-b-PSD
copolymer from the complex surface. Cell viability experi-
ments showed that polyplexes were non-toxic at pH 7.4, but
that cell viability was decreased to 20% at pH 6.6. Transfec-
tion studies showed a 10-fold increase in transfection when
altering the pH from 7.4 to 6.6. The authors noted that a
disadvantage of this system is that the detached copolymers
are nondegradable and the aggregates formed may be toxic.
Acid-triggered shedding represents a straightforward
approach. Among the acid-releasable coatings investigated
so far, the diorthoester and the hydrazone-linked coatings are
probably the most advanced. The diorthoester linkage has
fast hydrolysis kinetics and a relatively mild pH decrease
already induces shedding (29). That makes the system most
attractive for extracellular shedding in tumors and inflamma-
tory tissue.
Reduction-Induced Shedding
Bioconjugation using reduction-sensitive linkers has
been a popular approach in the design of drug delivery
systems (for a review see (48)). The disulfide bond (-S-S-) is
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formed by oxidation of two sulfhydryl groups and can be
cleaved by reducing agents. Extracellularly, due to the
oxidizing environment, formation or maintenance of the
disulfide bond is favored. The high cytosolic concentration
of sulfhydryl group-carrying molecules (e.g. glutathion)
creates a reductive environment and cleavage of the disulfide
bond occurs relatively quickly under these conditions.
Moreover, reduction of these bonds can take place at the
cell surface catalyzed by cell surface-associated redox
enzymes and in the endo/lysosomal compartment due to the
presence of e.g. cysteine and redox enzymes. Therefore, for
particulate carriers bearing a sheddable coating that responds
to changes in the redox potential, improved cellular interac-
tion, enhanced endosomal escape, and/or cytosolic destabili-
zation of the carrier can be envisaged. Molecular structures
of the conjugates used as coatings to achieve reduction-
induced shedding are summarized in Fig. 3.
Zalipsky and colleagues stabilized DOPE liposomes by
incorporation of 3-6 mol% of a disulfide-linked PEG
conjugate. PEG was coupled to distearoyl phosphatidyletha-
nolamine (DSPE) via 3,3¶-dithiopropionate (DTP) as linking
moiety (PEG-DTP-DSPE, Fig. 3a) (49). Shedding was
evaluated by dye release and lipid mixing studies. No leakage
of liposome contents occurred upon incubation in buffer (pH
7.2) or serum at 37-C for 36 h. Yet, in the presence of 10 mM
dithiothreitol (DTT), a complete release of the encapsulated
dye and lipid mixing was observed (50% release and lipid
mixing within approximately one hour), likely as a result of
shedding and subsequent liposome destabilization. DOPE/
CHEMS/PEG-DTP-DSPE liposomes (cholesteryl hemisucci-
nate (CHEMS) was included to achieve pH sensitivity),
retained an encapsulated dye in buffer of pH 5.5 at 37-C
during at least one day. When DTT or cell-free extracts to
mimic intracellular environments were added, liposomes
released their contents within a time-scale of hours (49,50).
After detachment of the PEG chains, the phospholipid
derivative 3-mercaptopropionyl-DSPE, was retained on the
liposome surface, which might hinder contact between
bilayers of the fusogenic liposomes and therefore be respon-
sible for additional stabilization (49). In vitro toxicity and
nuclear accumulation studies of doxorubicin (DXR) loaded
liposomes showed that formulations with the cleavable PEG
conjugate were not more cytotoxic than the formulation with
the non-cleavable PEG conjugate. Nevertheless, a faster
nuclear accumulation of DXR over a period of 12 h was
seen for the PEG-DTP-DSPE containing formulation (50).
Survival studies performed in a murine model of B-cell
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62 Romberg, Hennink and Stormlymphoma demonstrated an improved therapeutic efficacy of
doxorubicin encapsulated in anti CD19-targeted DOPE/
CHEMS/PEG-DTP-DSPE liposomes as compared to the
non-cleavable formulation at the same doxorubicin dose
(1.5 times increased life span in mice). Surprisingly, DOPE-
based liposomes stabilized with up to 8 mol% of the
cleavable PEG conjugate did not yield improvement of
circulation times in mice when compared to non-coated
liposomes, possibly caused by rapid cleavage of the disulfide
bridges in the circulation.
To avoid this rapid cleavage, a dithio-3-hexanol linker
was evaluated to link PEG to 1,2-distearoyl-sn-glycerol-3-
phosphatidic acid (PEG-DTH-DSPA, Fig. 3b) (51). The
attack of the DTH linker is sterically hindered by a propyl
group, which was expected to result in a higher stability of
the disulfide bond. And indeed, PEG-DTH-DSPA contain-
ing liposomes showed similarly prolonged circulation times as
compared to liposomes coated with non-cleavable PEG.
Studies on release of doxorubicin in the presence of 5 mM
DTT showed that all PEG-coated formulations released the
drug relatively slowly, in a time scale of hours. An exception
was the formulation with 15 mol% of PEG-DTH-DSPA,
which showed enhanced leakage as compared to the non-
cleavable formulation at pH 7.4, likely mediated by shedding
of the PEG-coating: approximately 90% of the liposomal
DXR was released over 24 h of incubation in case of the
cleavable formulation versus less than 25% release in the
case of the non-cleavable one.
To improve the reductive shedding approach, an alter-
native class of reduction-sensitive linkers to couple PEG to
DSPE was designed (Fig. 3c) (52). Dithiobenzyl carbamate
linkers (DTB, in o- and p- configurations) were expected to
be cleaved under mild thiolytic conditions due to their mixed
aliphatic and aromatic nature. Furthermore, as an amine
endgroup was generated after cleavage rather than the bulky
mercaptopropionyl derivative in case of the DTP linker, an
improved restoration of fusogenicity after shedding of the
coating was expected. The conjugates were susceptible to
cleavage in the time scale of minutes in an already mild
reductive environment (150 mM cysteine) as shown by HPLC
analysis, even when attached to a liposome surface. When 3
mol% of PEG-DTB-DSPE was incorporated into DOPE
liposomes, this formulation showed no contents release in
buffer at pH 7.2 and 37-C within at least 60 min of
incubation, but did release an encapsulated dye within 60
min when mild reducing conditions were applied. After
prolonged exposure to a low concentration of 15 mM
cysteine, which is the average concentration found in plasma,
a slight content release was also observed (10-20% within 60
min), indicating that the conjugates were possibly even too
trigger-sensitive and that drug release may already take place
during circulation.
A different shedding approach was pursued by Maeda
et al. (53). To avoid drug inactivation in the endo/lysosomal
compartment, fusogenic liposomes with a reduction-sensitive
sheddable PEG-coating and R8 cell-penetrating peptide
coupled to the liposome surface were designed. Shedding of
part of the PEG molecules was proposed to occur in the
vicinity of the cell surface and should lead to exposure of the
cell-penetrating R8 peptide, which would promote uptake by
plasma membrane translocation. Further removal of the
PEG-coating in the cytosol was proposed to lead to
destabilization of liposomes and consequently drug release.
A PEG-S-S-DOPE conjugate (Fig. 3d) was synthesized and
incorporated into calcein containing phosphatidylcholine
(PC)/DOPE/CHEMS/R8 liposomes at a level of 5 mol%. In
the absence of a reducing agent, calcein was not released
within 24 h. In the presence of 30 mM cysteine, only
approximately 10% release was observed after 24 h. With
240 mM cysteine a maximum release of 30% was reached
after 7 h, with 10 mM glutathione release was fast, but
incomplete (approximately 70% release within 4 h). Inter-
nalization of calcein-loaded liposomes was studied using
A431 cells. Liposomes with the cleavable PEG-coating were
internalized in a cysteine concentration-dependent manner.
Relatively low cysteine concentrations of e 30 mM, for which
no calcein release was observed, resulted in internalization of
the carrier. Furthermore, it was demonstrated that cysteine
was essential for plasmid delivery and transfection. The
authors conclude that at mild reducing conditions, which
may be encountered at the potential target sites, part of the
PEG molecules are cleaved off with display of the R8 peptide
as a result. After arrival in the cytosol, destabilization of the
carrier can occur at the higher concentrations of reducing
agents encountered.
Results of Carlisle et al. show the first successful
reduction-induced shedding approach for polyplexes (54).
DNA/PEI complexes with thiol groups were surface-coated
with pyridyldisulfanyl groups-containing polyHPMA as a
Fstealth_ coating, generating a disulfide linker between PEI
and polyHPMA. Polyplexes did not release DNA upon
incubation with a polyanion, indicating sufficient stabiliza-
tion. In the presence of 20 or 40 mM DTT, however, DNA
was released after 2 hrs of incubation. Transfection activities
of polyplexes with the reducible linker were 40-fold higher
than those obtained with polyplexes with a non-cleavable
linker. Increasing cytosolic reducing activity by co-delivery of
glutathion monoethyl ester resulted in increased transfection
levels, whereas co-delivery of a glutathion-inhibitor de-
creased transfection levels, demonstrating a clear role for
shedding in this approach. The applicability of using poly-
HPMA to prolong polyplex circulation times in vivo,
however, remains to be evaluated.
Shedding triggered by high redox-potentials in tissues is
an appealing strategy, as demonstrated by the various
research groups (49–54). However, often high concentrations
of reductive agents are required which are not present in
physiological/pathological environments (49). Nanoparticles
are mainly taken up by endocytosis, however, disulfide
reduction is a slow process under the acidic conditions
encountered in the endo/lysosomal compartment (55). The
cytosol is the location with the highest concentration of
reducing agents the carrier can encounter and therefore the
best shedding site. Particles which are taken up by endocy-
tosis, however, might not reach the cytosol and therefore the
applicability of these systems might be limited.
Proteolysis-Induced Shedding
Cleavage of a peptide linker located between the coating
polymer and its anchor requires the presence of proteolytic
enzymes as encountered e.g. in the endo/lysosomal compart-
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proteases are associated with a high protein and peptide
turnover. Furthermore, proteolytic enzymes, e.g. lysozymes
and cathepsins, are also present extracellularly in patholog-
ical sites that involve tissue-remodeling states such as
inflammatory and malignant areas (56–58).
Zhang et al. investigated the feasibility of proteolysis-
induced shedding (51). A small peptide (Gly-Phe-Leu-Gly), a
substrate for e.g. cathepsin B, was used to conjugate PEG
with DSPE (PEG-GFLG-DSPE). DOPE/CHEMS liposomes
prepared with 15 mol% of the cleavable PEG conjugate
showed prolonged circulation times. However, release of
doxorubicin from these liposomes at pH 5.5 was not
improved in the presence of cathepsin B when compared to
liposomes incubated without cathepsin B. This relatively
disappointing result was attributed to slow cleavage kinetics
and/or increased stability due to the retention of lipids with
peptidylaminoethanol groups in the bilayer.
Hatakeyama et al. designed a PEG-peptide–DOPE
conjugate (PPD) to stabilize DNA polycation complexes
based on DOTAP, DOPE and cholesterol (referred to as
multifunctional envelope-type nanodevice, MEND) during
circulation. Cellular interaction was aimed to be facilitated
by means of shedding of the PEG-coating after cleavage of
the peptide linker by matrix metallo proteinases (MMP)
which are secreted by tumor cells into the extracellular space
(59). The PPD conjugates were cleaved in the presence of
MMP-2 (14 and 56 nM) as confirmed by MALDI-ToF mass
spectrometry analysis. When attached to liposomes, an
increase in liposome size was observed after 24 hrs of
incubation with MMP-2, indicating HII-transition of DOPE.
The transfection efficiency of PPD-MEND was analyzed
using a MPP expressing cell line (HT1080 fibrosarcoma cells)
and a non-MMP expressing cell line (HEK293 cells). As an
example, the transfection efficiency of PPD-MEND with 5%
MEND was 35-fold higher in HT1080 cells than that of
MEND with a non-cleavable PEG. Circulation time studies
in mice revealed that PPD prolonged circulation time of
MEND significantly; however, circulation times of MEND
with a non-cleavable PEG were superior. Tumor accumula-
tion of PPD-MEND was increased when compared to non-
coated MEND. In vivo transfection studies in tumor tissue
after i.v. administration showed a superior transfection effect
of PPD-MEND when compared to PEG-MEND. This study
clearly shows promise for the applicability of systems with a
proteolytically cleavable linker, exploiting enzymes present
within the (patho-)physiologically environment.
Shedding by Spontaneous Extraction
Out of the Nanoparticles
Conjugates of lipids and hydrophilic polymers are
generally able to diffuse out of membranes depending on
the strength of the anchorage (60). Silvius and Zuckerman
investigated the transfer of several phospholipid–polymer
conjugates between phospholipid vesicles using fluorescence
resonance energy transfer (FRET). Their results suggest that
hydrophilic polymers grafted to lipid bilayers by hydrophobic
anchors with 18 carbons or less may generally be able to
transfer between membranes, with half lives up to several
tens of hours, depending on the anchor chain composition.
The strength of the interaction between the anchor moiety
and the membrane lipids determines the rate and extent of
extraction.
Five types of exchangeable PEG–lipid conjugates have
been studied as sheddable Fstealth_ coatings on liposomes or
lipoplexes (Fig. 4): PEG–phosphatidylethanolamine conju-
gates, PEG–ceramide conjugates, PEG–diacylglycerol con-
jugates, PEG–dialkyloxypropylamine conjugates and PEG–
SAINT conjugates.
PEG-Phosphatidylethanolamine Conjugates
The group of Madden investigated the transfer of PEG-
diacyl-sn-glycero-3-phosphoethanolamine (PEG-PE, Fig. 4a)
conjugates out of large unilamellar, fusogenic DOPE/PS
liposomes to neutral acceptor Fsink_ liposomes (13). Calci-
um-induced fusogenic activity of the DOPE/PS liposomes
was inhibited by low amounts of PEG-lipids, but completely
restored upon extraction of the PEG-lipids. The fusion rate
was dependent on the acyl chain length (DMPE (C14)>
DPPE (C16) > DSPE (C18)) and the degree of saturation of
the anchoring acyl chain (unsaturated > saturated).
Programmable fusogenic vesicles (PFV) that exhibit
time-dependent destabilization were designed to achieve
disease-site selective leakage of the incorporated drug (61).
PFV were composed of the non-bilayer forming lipid DOPE,
cholesterol, the cationic lipid N,N-dioleyl-N,N-dimethylam-
monium chloride (DODAC) to promote cell binding and 10
mol% of PEG-PE lipids with different acyl chain lengths
(DMPE, DPPE and DSPE) to shield the positive charge and
to stabilize the bilayer conformation. Circulation time studies
in mice showed that the PEG-PE formulation with the
shortest acyl chain (DMPE) were rapidly eliminated from
the circulation, in agreement with a fast extraction of the
conjugate, while the formulations with the DPPE and DSPE
anchor were circulating considerably longer (50% present in
the circulation at 4 h and 24 h, respectively). Studies in a
human colon carcinoma xenograft model showed, that PFV
prepared with PEG-DSPE and containing the anticancer
drug mitoxantrone had a higher antitumor activity after
intravenous administration as compared to the PEG-DMPE
containing formulation, likely due to superior circulation
kinetics of the former type resulting in higher drug levels in
tumor tissue.
An assay based on biotin-streptavidin interaction was
applied by the group of Bally to study the potential of
exchangeable PEG-lipids to temporarily shield targeting
ligands which were attached to the liposome surface (62). A
functional, indirect assay was used to assess the generation of
a surface shield on biotinylated acceptor liposomes. Li-
posomes prepared with PEG–PE conjugates with different
acyl chain lengths were used as PEG-PE donor liposomes.
Transfer of the PEG conjugates to the acceptor liposomes
was studied in a biotin binding assay using streptavidin (SA)-
coated magnetic particles. Whereas PEG-DSPE was not able
to transfer to the acceptor liposome population as reflected
by unaltered binding of the acceptor liposomes to SA, PEG-
DMPE was transferred significantly at the time-scale of
minutes at 37-C. To measure PEG–lipid conjugate extraction
in vivo, biotinylated liposomes shielded with different PEG–
64 Romberg, Hennink and StormPE conjugates were administered intravenously into mice.
Plasma was collected after 16 h. Subsequently the binding
assay using SA-coated magnetic particles was performed.
Extraction rates in vivo were comparable to the data
obtained in vitro. The PEG-DSPE formulation did not show
binding activity, indicating that the conjugate was not
extracted from liposomes. The PEG-DMPE and a PEG-
DOPE formulation, on the other hand, showed 63% and
41% of the binding activity which was observed for non-
PEGylated formulations after circulation in vivo. As the
PEG–lipid conjugate transfer process occurs over a time
scale of hours for PEG-DPPE or PEG-DOPE, a time scale
allowing for significant liposome accumulation in tumors, the
authors conclude that these systems can serve for actively
targeted long-circulating liposomes exposing their targeting
ligand in the tumor by shedding. To evaluate this system
further, the potential of the different exchangeable PEG-
lipids to protect the model targeting ligand biotin from
interaction with specific antibodies was investigated using
PC/cholesterol liposomes with 0.1 mol% of a biotin–conju-
gated lipid (63). In an in vitro antibody consumption assay,
complete protection of the ligand with the usually applied
5 mol% of PEG conjugate could only be obtained when
using PEG-DSPE or PEG-DPPE, the conjugates with
longer acyl chains. Mice with an existing immune response
against biotin were challenged with these liposomes. It was
observed that only for formulations that showed no
antibody binding in vitro, effective protection against rapid
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Fig. 4. Chemical structure of PEG–PE, PEG–Ceramides, PEG–diacylglycerols, PEG–dialkyloxypropylamines and PEG–SAINT.
65 Sheddable Coatings for Long-Circulating Nanoparticleselimination of the liposomes in vivo occurred. PEG-DMPE,
the conjugate with the shortest acyl-chains, was not able to
prolong liposome circulation times, likely as a result of its
rapid extraction.
The influence of different PEG conjugates on the in
vitro transfection efficiency of lipid-DNA particles (LDP)
composed of plasmid DNA, n-octyl-D-glucopyranoside,
DODAC, DOPE and exchangeable PEG-lipids was investi-
gated (64). PEG-DSPE was used as a slow exchanging
conjugate, and compared to PEG-DOPE and PEG-DMPE.
All three formulations showed a significantly reduced trans-
fection of B16/BL6 melanoma cells when compared to a non-
PEGylated formulation. LPD with PEG-DMPE were the
most transfection potent with still measurable gene expres-
sion at 10 mol% coating density due to extraction from the
bilayer. For PEG-DSPE LPD and PEG-DOPE LPD com-
plete suppression of transfection was observed at Q 5 mol%
coating density and Q 2 mol% coating density, respectively.
Mayer and colleagues studied the applicability of
exchangeable PEG–PE conjugates on the surface of li-
posomes containing 10 mol% phosphatidylserine (PS) (65).
PS liposomes are able to induce coagulation by binding of
clotting factors and, when delivered specifically to tumor
sites, this coagulation can result in tumor regression. How-
ever, PS liposomes have to be shielded during circulation to
avoid intravenous coagulation and rapid elimination. Li-
posomes with a PEG-conjugate grafting density of 10–15
mol% were used. Forty percent of the PEG–DMPE conju-
gate was extracted out of the liposomes within 15 min after
addition of acceptor PC/cholesterol liposomes. For the PEG–
DPPE conjugate the extraction rate was 45% in 24 h.
Transfer only occurred in the presence of acceptor liposomes.
PEG-DSPE was not transferred to a significant extent within
24 h. The clotting activity, resulting from exposure of the PS
on the liposome surface after detachment of the PEG-
coating, was assessed by measuring the partial thromboplas-
tin time. While inhibition of clotting activity was constant
over 24 h for the PEG-DSPE containing PS liposomes, for
the PEG-DMPE PS liposomes the inhibition of clotting
activity decreased to less than one third of its original value
within 15 min, likely caused by shedding of the liposome
coating. For PEG-DPPE containing liposomes inhibition of
clotting activity was reduced by half within 8 h. Circulation
time studies in mice showed that plasma levels of PEG-DSPE
PS liposomes were clearly higher than those of the formula-
tions containing PEG-DMPE and PEG-DSPE (more than
30% of the injected dose in the circulation at 4 h post-
injection). For the latter formulations, less than 1% of the
injected dose was still in the blood stream 4 h after
administration. The authors conclude that the surface reac-
tivity of PS-containing liposomes can be controlled by
utilizing exchangeable PEG-lipids.
PEG–Ceramide Conjugates
PEG–ceramide conjugates (PEG–Cer, Fig. 4b) were
proposed as alternatives for PEG-PE by the group of
Madden (13). Cullis and coworkers compared PEG–Cer
conjugates with various acyl chain lengths (66). Coating of
liposomes with 5 mol% of PEG–CerC20 and PEG–CerC24
conjugates resulted in prolonged circulation times in mice,
comparable to liposomes prepared with PEG-DSPE. How-
ever, PEG coupled to shorter C8 and C14 ceramides did not
alter i.v. pharmacokinetics as compared to non-coated li-
posomes, this likely as a result of rapid extraction of PEG-
ceramides out of the liposomes after i.v. administration.
PEG-ceramides were also utilized to temporarily stabi-
lize fusogenic, cationic liposomes for gene delivery purposes,
with the aim to restore fusogenic activity by shedding of the
coating after arrival at the target site (67). Fusogenic activity
of liposomes was dependent on the acyl-chain length, as
assessed by a lipid mixing assay. At 5 mol% PEG-CerC20
suppressed lipid mixing to a greater extent than PEG-CerC14
(approximately 15% vs. 5% lipid mixing after 50 min of
incubation). Circulation times in mice also were acyl-chain
length- and therefore exchangeability-dependent, with for-
mulations with longer chains being more potent stabilizers,
resulting in more prolonged circulation times. For example,
30% of PEG-CerC20 liposomes and only 7% of PEG-CerC8
liposomes were in the circulation 1 h after administration.
PEG-ceramides were also tested in SPLP formulations.
SPLP composed of DOPE/DODAC, plasmid DNA and 10
mol% PEG-Cer were produced by detergent dialysis (68). As
expected, in vitro extraction was dependent on the acyl chain
length. Conjugates with C8 and C14 chains were transferred in
the time frame of minutes (1.2 min and approx. 70 min,
respectively), PEG-CerC20 stayed attached to the bilayer for
up to 13 days (68,69). The in vitro transfection efficiencies
were also dependent on the length of the ceramide acyl
chain. Inclusion of 10 mol% PEG-CerC14 resulted in
approximately 10-fold higher gene expression in COS-7 cells
as compared to the PEG-CerC20 containing formulation after
5 days of incubation (68). A 30-fold higher transfection level
was achieved with SPLP containing PEG-CerC8 as compared
to those prepared with PEG-CerC14 in BHK cells (70).
Likely, there is a correlation between transfer rates and
transfection efficiency; formulations with shorter acyl chains
have a higher potential to associate with the cell membrane
and fuse with the endosomal membrane after endocytosis.
Pharmacokinetic studies in mice revealed that SPLP contain-
ing PEG-CerC20 remained in the circulation for hours,
whereas the PEG-CerC8-a n dP E G - C e r C 14-counterparts
were cleared in 5 and 30 min, respectively, which was likely
a result of faster extraction and subsequent opsonization and
uptake by macrophages (69,71). The authors argue that
conjugates with C16 or C18 alkyl chains might provide carriers
with more optimal properties. However, this argument needs
further experimental substantiation. SPLP with PEG-CerC20
were shown to be able to also transfect tumor cells in vivo
(69,71,72). With this formulation, 43-fold more plasmid was
delivered into the tumor site than with PEG-CerC14 SPLP.
The role of shedding in successful in vivo transfection of
PEG-CerC20 containing SPLP, however, remains unclear.
Programmable fusogenic liposomes (PFV, see PEG-
Phosphatidylethanolamine Conjugates) prepared with PEG-
ceramides were investigated by Hu and colleagues for the
delivery of antisense ODN. PVF consisting of DOPE,
DODAC, cholesterol and PEG-ceramides of different acyl-
chain length were used (73). It appeared that PVF with PEG-
CerC14 yielded the best results regarding cytosolic delivery of
ODN to HEK 293 cells when compared to PEG-CerC8 and
PEG-CerC20 PVF. ODN containing PVF with PEG-CerC14
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than non-coated control DOPE/DODAC/ODN liposomes,
possibly related to the time needed for shedding and
destabilization. Song et al. studied the effect of varying the
acyl-chain length of PEG–Cer conjugates on the gene and
antisense transfer into cells with cationic DOPE/DODAC
liposomes (74). Anti-luciferase ODN-loaded liposomes with
PEG-CerC20 were not able to inhibit luciferase expression, the
formulations with C14 and C8 ceramide anchors, however,
showed significantly inhibited luciferase expression.
Shi et al. studied lipoplexes composed of DOPE, the
cationic lipid N-methyl-4-(dioleyl)methylpyridinium chloride
(SAINT-2) and PEG-CerC8, PEG-CerC14 or PEG-CerC20
for the cellular delivery of ODN (75). Association with CHO
cells and nuclear accumulation was dependent on ceramide
chain length. After 2 h of incubation, nuclear accumulation of
ODN was only seen for the formulation containing the PEG–
CerC8 conjugate. Overnight incubation of the cells with
lipoplexes containing the PEG–CerC8 and PEG–CerC14
conjugates resulted in effective nuclear delivery and some
delivery was seen for lipoplexes with PEG-CerC20 lipoplexes.
The antisense effect of lipoplexes in downregulation of CRF-
R expression in CHO cells was inversely correlated with the
acyl chain length (C8>C14>C20) which indicates that shedding
of the PEG-coating is an essential requirement for the
efficient delivery of ODN.
Stabilized antisense-lipid particles (SALP) composed of
PC, cholesterol, DODAP, PEG-ceramide and antisense
ODN were used to study the influence of the exchangeability
of the PEG-coating on the immunogenicity of the carrier
(22). Exchangeability was desired to abrogate the immunos-
timulatory effect of nucleic acids formulated in PEG-li-
posomes. When the slowly exchangeable PEG-CerC20 was
used as a stabilizing conjugate, particles were rapidly
eliminated after a second injection. PEG-reactive IgM was
detected in the blood of treated animals. Using PEG-CerC14,
where more than 50% of the conjugate was removed from
the carrier within 3 min after administration, subsequent
injections showed no differences in circulation kinetics,
indicating a much weaker immune response than for the
PEG-CerC20 containing formulation.
PEG–Diacylglycerol Conjugates
Ambegia et al. designed an SPLP formulation based
DODAC and DOPE with a exchangeable coating using 10
mol% PEG-succinoyl 1,2-diacylglycerol (PEG-S-DAG,
Fig. 4c) (76). These conjugates were easier to synthesize and
purify than PEG-ceramide conjugates. PEG-DMG (C14),
PEG-DPG (C16), and PEG-DSG (C18) were incorporated
into SPLP and compared to PEG-ceramide containing SPLP
regarding pharmacokinetics, biodistribution, and transfection
properties. A lipid transfer assay based on FRET was used to
analyze fusogenic properties of SPLP in vitro in the presence
of Fsink_ liposomes. SPLP prepared with PEG-DMG (with
the shortest alkyl chain) were twice as fusogenic as compared
to SPLP containing PEG-S-DAG with the longer alkyl
chains. In line with these results, SPLP with the PEG-DMG
yielded also the highest levels of gene expression in Neuro 2a
cells. However, circulation time studies in mice showed that
the SPLP formulation with the best in vitro performance
(C14) was cleared very rapidly, likely due to a fast extraction
of the PEG-coating. Both SPLP formulations with PEG
coating anchored via the longer alkyl chains had comparable
circulation times as compared to SPLP with PEG-CerC20.I n
mice bearing a s.c. Neuro-2a tumor, tumor accumulation
(12% injected dose/g tumor) and tumor gene expression was
also highest for SPLP with PEG-DSG and PEG-DPG and
comparable to SPLP with PEG-CerC20.
Judge et al. designed a carrier for the administration of
nucleic acids (21). They observed that repeated administra-
tion of SPLP containing 10 mol% PEG-S-DSG was associ-
ated with accelerated blood clearance and loss of gene
expression and anti-PEG IgM and IgG were found. For
SPLP containing PEG-S-DMG, the conjugate with shorter
acyl chains and faster exchange rates, only low titers of IgM
and no IgG were measured and no signs of toxicity were
observed unlike with SPLP with the PEG-conjugate with a
longer anchor. Tumor accumulation and gene expression of
the SPLP with PEG-S-DMG were only twofold lower than
with PEG-S-DSG. Expression after repeated administration
of PEG-S-DMG SPLP was unaltered and blood clearance
was only weakly affected.
PEG-Dialkyloxypropylamine Conjugates
Heyes et al. demonstrated that both PEG-S-DSG and
PEG-CerC20 were chemically unstable in lipoplex formula-
tions due to the presence of carboxylic ester bonds in the
succinate linker (77). Alternative linkers to couple PEG to
1,2-distearyloxypropyl-3-amine (DSA) and 1,2-dimyristylox-
ypropyl-3-amine (DMA), among which the carbamate linker
(PEG-C-DSA, PEG-C-DMA, Fig. 4d), were synthesized.
Circulation time studies in A/J mice showed that SPLP
containing PEG-C-DSA had a circulation half-life of 16 h,
whereas PEG-C-DMA containing SPLP were cleared much
more rapidly with a half-life of 2 h. The results regarding
tumor gene delivery were comparable to those obtained with
PEG-DAG with a lower gene expression for SPLP contain-
ing PEG-C-DMA than with SPLP containing PEG-C-DSA.
PEG–SAINT Conjugates
Reijman et al. synthesized exchangeable PEG conju-
gates employing the cationic lipid N-methyl-4-alkylpyridi-
nium chloride (SAINT) as lipid anchor (Fig. 4e) (78).
Lipoplexes of DOPE, a cationic lipid, a reporter plasmid
with or without 5 mol% of PEG-lipids, respectively, were
prepared. The exchangeability of the PEG–SAINT conju-
gates was assessed in a DNA release assay in the presence of
anionic vesicles to mimic endosomal escape and PC li-
posomes as acceptor membranes for the PEG conjugates.
Exchange behavior was dependent on the alkyl-chain length.
For the PEG-SAINT12:0 and the PEG-SAINT14:0 formula-
tions (the subscript gives the number of carbon atoms per
alkyl chain and the number of double bonds), DNA release
was complete after 1–2 h and 8–10 h, respectively, whereas
the PEG-SAINT18:0 formulation did not release DNA over a
period of 18 h. Transfection results showed the same acyl-
chain length dependency. While lipoplexes prepared with the
longest PEG–SAINT conjugate (C18) and PEG-DSPE
showed no transfection of B16 melanoma cells after 3 days,
67 Sheddable Coatings for Long-Circulating Nanoparticleslipoplexes with the C12 and C16 anchors yielded about 60%
transfected cells (comparable to the transfection activity of
non-PEGylated formulations).
Table II summarizes approaches with shedding by
spontaneous extraction out of the nanoparticle. For the
conjugates with a PE anchor, acyl chain length dependent
fusion could be demonstrated (13), however only PEG-DSPE
showed long circulation times (61). Especially the PEG–
ceramide conjugates were extensively studied. Particles with
PEG–CerC8 conjugate showed significant transfection in
vitro but no prolonged circulation times and transfection in
vivo (70). Particles with the C20 chain PEG-ceramide on the
other hand that circulate sufficiently and transfect solid
tumors in animals did not show high transfection levels in
vitro (72). For exchangeable PEG–lipid conjugates in gener-
al, nanoparticle design is a compromise between prolonga-
tion of circulation times and protection of the carrier on the
one hand, and a sufficient interaction of the carrier with the
target and delivery on the other hand.
Shedding by Degradation of the Coating Material Itself
Besides coating conjugates with degradable linkers or
exchangeable conjugates, shedding may also be pursued by
the use of coating materials, which are fully biodegradable.
Yet, these materials have to be able to act as Fstealth_
coatings in the first place. In one approach, PEG has been
chemically modified to introduce reduction-dependent deg-
radation properties (79). The modified PEG polymer is
sensitive to changes in redox-potential as a result of the
introduction of disulfide bonds into the polymer backbone
(poly(ethylene oxide sulfide), PEOS). The disulfide bonds
were cleaved within two hours when exposed to reducing
conditions resembling those encountered in the cytosol.
Although circulation kinetics of nanoparticles coated with
this material have not been studied yet, the potential of this
material as a sheddable Fstealth_ coating is obvious.
Recently, our research group reported on two poly
(amino acid)-coatings based on (poly(hydroxyalkyl L-aspara-
gine) (PHEA) and poly(hydroxyalkyl L-glutamine) (PHEG,
Fig. 5)( 8). Polypeptides of approximately 20 amino acids
coupled to a lipid anchor were synthesized. The enzymatic
degradability of the PHEG conjugate was demonstrated
using the model proteases papain and pronase E, and the
lysosomal enzyme cathepsin B, the latter being also present
extracellularly in tumors and inflammatory tissue (80). All
tested proteases were active towards the PHEG conjugate
and degradation resulted in small peptide fragments. Li-
posomes coated with PHEA and PHEG showed almost
similar circulation behavior in rats as compared to coating
with PEG-DSPE (8).
There are only very few examples of fully degradable
coatings for nanoparticles and only little is known about their
degradation kinetics in vivo until now (see Table III for
shedding approaches using degradable coating material).
Nevertheless, these coatings represent an interesting alterna-
tive to linker-based shedding approaches.
SUMMARY AND CONCLUSION
Above, different shedding approaches have been high-
lighted. The choice of the most useful approach is dependent
on factors like the presence of stimuli at the aimed shedding
site (in the case of degradable linkers/coatings: low pH, low
redox potential, proteolytic enzymes). To avoid dependence
on such stimuli, exchangeable coatings have been designed.
However, in the latter case it is obvious that the rate of
exchange should be tailored to the needs of the applications.
In principle, the shedding approaches can also be categorized
as follows (see also Fig. 1): Extracellular shedding in
pathological or healthy tissue should lead to an enhanced
drug release, with subsequent uptake of the free drug by the
target cell (29,34,61,66,80). Or exposure of a targeting ligand
(62,63), charge (33,39,47,59,64), cell-penetrating peptide
(40,53) or fusogenic moiety (67,73) Fburied_ in the steric
coating can be achieved by shedding, which would facilitate
interaction of the particles with the cell membrane possibly
followed by internalization. Intracellular shedding would lead
to drug release within the endosome or interaction with the
endosomal membrane for cytosolic release of the cargo
(30,32,35,36,41,42,44,46,50,51,54,74,78,80). Also, shedding of
the coating within the cytosol from particles which have been
translocated over the plasma membrane has been proposed
as cytosolic delivery mechanism (53). In addition, shedding-
induced exposure of PS for tumor site specific coagulation
(65) and shedding to reduce immunogenicity of nucleic acid
containing PEG-coated carriers have been investigated
(21,22,77). As the shedding process in case of the carriers
with exchangeable coatings are not dependent on the
presence of a stimulus, the body location(s) where shedding
occurs is governed by the kinetics of the exchange process
and can be extra- or intracellular (61,64,66,74). Among the
degradable coatings, both degradable linkers and degradable
coatings are applied. The advantage of a degradable linker
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Fig. 5. Chemical structure of PHEG–lipid conjugate (n$20).
68 Romberg, Hennink and Stormmay be that only one bond per polymer chain needs to be
cleaved to detach a complete coating molecule from the
carrier surface. This might imply a much faster and probably
more complete shedding than when a fully degradable
coating is applied, where more than one bond per coating
molecule needs to be broken before the chains will be short
enough to allow exposure of surface characteristics or
destabilization. It should be realized, however, that a single
linker bond, which is located deeply inside the shielding
layer, might be quite inaccessible for the stimulus. For
instance, a peptide linker might be difficult to reach for the
proteolytic enzyme with obviously insufficient shedding as a
result.
The shedding rate is a crucial parameter that has to be
addressed when designing sheddable coatings. If premature
shedding occurs, the unprotected carrier will likely be rapidly
cleared from the circulation (50,52,61,62,66,76). On the other
hand, if shedding occurs at a too slow rate the therapeutic
efficacy of the incorporated active agent may be too low
(35,36,49,51,62,64,68,74,78). Moreover, if shedding is incom-
plete, interaction of the carrier with its target or drug release
might be poor.
Shedding of a stabilizing nanoparticle coating is an
elegant tool to optimize the performance of particulate
carriers in drug delivery. It would enable a controlled
alteration of the properties of a particulate carrier on its way
to the target, with the ultimate goal to improve the delivery of
its cargo. In the past ten years investigations of several
research groups generated promising results. FSmart_ chemis-
try allowed the design of functional conjugates, which for
example respond to different stimuli present in the human
body. However, it still remains a challenge to optimize the
efficiency of these systems for successful in vivo application.
Although several groups claim tailorable properties of their
system, actual improvements in terms of drug delivery are
only scarcely demonstrated. Most shedding studies so far
were performed in vitro with a lack of demonstration of
shedding under in vivo conditions. In this field, there is a lot
of suggestion and only indirect evidence of shedding has been
obtained in functional assays (e.g. transfection potency of a
DNA loaded carrier). The design of studies on the shedding
process itself and its kinetics in vivo is obviously difficult.
Nevertheless, the current status reflects promising achieve-
ments on the road to the design of particulate nanomedicines
with optimal therapeutic performance.
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